TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03343418

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% saline is to be administered as an intravenous infusion after discontinuation of cardiopulmonary bypass and administration of protamine. Patients randomized to the control group will receive the infusion of 100 milliliters (mL) 0.9% saline (SF0,9%). After 0.9% saline infusion, bleeding treatment will follow the predefined standardized treatment regimen.
Study: NCT01463917

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Isotonic
Description: Use of Isotonic solution 4 ml/Kg during left marginal branch CABG surgery.
Study: NCT04047888

Intervention type: OTHER
Intervention: Non nutrition-based educational message
Description: No nutrition-based education on infant feeding and practices
Study: NCT02947919

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music
Description: A previously defined list of songs will be administered by headphones to these patients with an MP3 device with headphones.
Study: NCT00482092

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Prochymal® Placebo-matching IV infusion
Study: NCT06310863

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LASBEAU Strong or Restylane Lyft injection as hyaluronic acid fillers
Description: Subjects will be randomized to receive LASBEAU Strong or Restylane Lyft injections into each of the nasolabial folds on both sides.~LASBEAU Strong or Restylane Lyft Injection Box

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LASBEAU Strong or Restylane Lyft injection as hyaluronic acid fillers
Description: Subjects will be randomized to receive LASBEAU Strong or Restylane Lyft injections into each of the nasolabial folds on both sides.~LASBEAU Strong or Restylane Lyft Injection Box
Study: NCT03753906

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Osmed® hydrogel expander implantation
Description: Under local anaesthesia, a small vertical incision, adapted to the diameter of the Osmed® sself-inflating hydrogel expander, was made with #15 scalpel blade at the mesial line angle of the adjacent tooth which started below the gingival margin extending from the keratinized tissue above the MGJ to the non-keratinized tissue beyond the MGJ. A minimally invasive preparation of a subperiosteal pouch was performed with KPA tunnelling knife. Size of the pouch was controlled with the specific surgical template to ensure the device easily fits into the prepared pouch without tension. Expanders were secured in the correct position with a bone fixation screw, at the flat end, which does not possess an expansion capability. The wound was closed with 3-0 silk suture using simple interrupted sutures.
Study: NCT02050126

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lumenis UltraPulse Encore.
Description: Treatment using Lumenis UltraPulse Encore.
Study: NCT00564538

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anti-thymocyte globulin (rabbit)
Description: 1.5mg/kg per dose with the first dose initiated in the operating room prior to reperfusion of the transplanted liver. It will then be administered again on post operative day #1, 3 and 5 for a total cumulative dose of 6mg/kg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tacrolimus
Description: Tacrolimus will be administered orally on post op day #1 as per standard of care.
Study: NCT02242591

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine 7,5 mg/ml

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ropivacaine 7,5 mg/ml

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Study: NCT01535664

Intervention type: OTHER
Intervention: Withdrawal of dalfampridine-ER 10mg
Description: Withdrawal of dalfampridine-ER 10mg (7 days on study drug followed by withdrawal period of 10 days, followed by on study drug until study completion)~* On drug Day-7 (visit 1) through Day 1 (visit 2)~* Off drug Day 5±2 days (visit 3) through Day 11±2 days (visit 4)~* On drug Day 15±2 days (visit 5)
Study: NCT02858817

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atovaquone/proguanil 250mg/100mg (A/P)
Description: Combination drug for chemo-prophylaxis or treatment of malaria

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atovaquone/proguanil 250mg/100mg (A/P)
Description: Combination drug for chemo-prophylaxis or treatment of malaria

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: atovaquone/proguanil 250mg/100mg (A/P)
Description: Combination drug for chemo-prophylaxis or treatment of malaria

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PfSPZ Challenge (NF54)
Description: cryo-preserved Plasmodium falciparum sporozoites injected by venous inoculation

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PfSPZ Challenge (NF54)
Description: cryo-preserved Plasmodium falciparum sporozoites injected by venous inoculation

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: NaCl 0,9%
Description: 0.9% NaCl solution for injection
Study: NCT00911001

Intervention type: BEHAVIORAL
Intervention: No Drug
Description: Patients in daily life clinical treatment receiving pharmacological agents to prevent VTE.
Study: NCT01397097

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LNG-IUS (BAY 86-5028)
Description: LCS12 insertion will occur at randomization visit (Visit 2). Duration of study treatment is 12 months with an follow-up extension for up to 3 years

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 68 mg etonorgestrel implant for subdermal use (Nexplanon)
Description: Implant insertion will occur at randomization visit (Visit 2). Duration of study treatment is 12 months, may be continued up to 3 years under standard care.
Study: NCT04657107

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-ketamine
Description: K1 group: pregnant women received 0.2mg/kg S-ketamine, intravenous drip;

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: Saline group: pregnant women received saline, intravenous drip

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-ketamine
Description: K2 group: pregnant women received 0.3mg/kg S-ketamine, intravenous drip;
Study: NCT03757013

Intervention type: DRUG
Intervention: Apremilast
Description: Apremilast
Study: NCT03407300

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: To evaluate the safety and efficacy of Docetaxel alone in stage III-IV NSCLC patients

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: To evaluate the safety and efficacy of Docetaxel alone in stage III-IV NSCLC patients

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chinese traditional medicine XH1
Description: To evaluate the safety and efficacy of Docetaxel combined with Chinese tradition medicine XH1 in stage III-IV NSCLC patients
Study: NCT01419145

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multimodal intervention
Description: Nutritional supplements aimed at optimal energy balance and protein intake (2 cartons of ProSure per day), nutritional advice, home-based self-assisted exercise program and anti-inflammatory treatment (300 mg celecoxib) for 6 weeks. The aerobic exercise program is performed as self-administered daily walking sessions, aiming for a minimum of two sessions 30 minutes on a weekly basis. Other aerobic activities could be used instead of walking. The resistance exercise program should be performed 3 times weekly and lasts about 20 minutes. The program is targeting major muscle groups in the upper body and legs with use of weights. The intensity of the exercise and performance of the exercises are adapted to the individual patient's disease burden and physical performance.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Standard cancer care
Study: NCT01154023

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: stimulus control therapy, sleep restriction therapy, multi-component treatment (stimulus control therapy, sleep restriction therapy)
Description: Treatment was given weekly for 6 weeks. Sessions 1 - 4 were in a group format. Session 5 \& 6 were delivered individually by phone.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: stimulus control therapy, sleep restriction therapy, multi-component treatment (stimulus control therapy, sleep restriction therapy)
Description: Treatment was given weekly for 6 weeks. Sessions 1 - 4 were in a group format. Session 5 \& 6 were delivered individually by phone.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: stimulus control therapy, sleep restriction therapy, multi-component treatment (stimulus control therapy, sleep restriction therapy)
Description: Treatment was given weekly for 6 weeks. Sessions 1 - 4 were in a group format. Session 5 \& 6 were delivered individually by phone.
Study: NCT03130647

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Focused ultrasound
Description: Focused ultrasound
Study: NCT04184986

Intervention type: DIAGNOSTIC_TEST
Intervention: dry blood test
Description: screening test for Fabry disease

Intervention type: DIAGNOSTIC_TEST
Intervention: dry blood test
Description: screening test for Fabry disease
Study: NCT02269189

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIL 284 BS, high dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIL 284 BS, low dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03894722

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: During the third molar extraction the saline solution will be used in the control group.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 0.5% concentration of PVP-I
Description: During the third molar extraction 0.5% concentration of PVP-I solution will be used in the test group.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 1 % concentration of PVP-I
Description: During the third molar extraction 1 % concentration of PVP-I solution will be used in the test group.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 3 % concentration of PVP-I
Description: During the third molar extraction 3 % concentration of PVP-I solution will be used in the test group.
Study: NCT00362180

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mipomersen
Description: 200 mg subcutaneous injections

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mipomersen
Description: 200 mg subcutaneous injections

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mipomersen
Description: 200 mg subcutaneous injections

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mipomersen
Description: 200 mg subcutaneous injections

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: mipomersen
Description: 200 mg subcutaneous injections

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: subcutaneous injections

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: subcutaneous injections

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: subcutaneous injections

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: subcutaneous injections
Study: NCT04379492

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Participants will receive hydroxycholoroquine (200-mg tablets) 2 tablets orally q12h for 2 doses on day 1 (load), followed by 1 tablet orally q12h for days 2-5.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive masked placebo given as 2 tablets orally q12h for 2 doses on day 1, followed by 1 tablet orally q12h for days 2-5.
Study: NCT03821844

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music and Memory
Description: Music and Memory is a personalized music program in which caregivers (nursing home staff, family, or others) provide people with dementia with music playlists tailored to their personal history of music preferences.
Study: NCT02480140

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-regulated constraint-induced movement therapy
Description: There were 10 tasks to practice in total, they included fold laundry, put clothes on hanger, brush teeth, dress upper garment, dress lower garment in week one; and use telephone, prepare a cup of tea, sweep floor, wash towel, wash dishes in week two. In the 4 hours when the participants had their non-hemiplegic arm in the restrain, they received one hour therapist-guided training using SR strategy on task relearning as described above. Therefore, all participants received 10 one-hour therapist-guided training sessions (daily on weekdays, total two weeks). The intervention was delivered by occupational therapist. For the rest of the 3 hours in the restrain, the participants' wearing of the restrain was monitored by the nursing staff in the ward.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Constraint-induced movement therapy
Description: They practised the same 10 tasks as in the SR-CIMT and control groups. The same as the experimental intervention group (SR-CIMT), in the 4 hours when the participants had their non-hemiplegic arm in the restrain, they received one hour therapist-guided training using the strategy on task relearning as described above. Therefore, all participants received 10 one-hour therapist-guided training sessions (daily on weekdays, total two weeks). The intervention was delivered by occupational therapist. For the rest of the 3 hours in the restrain, the participants' wearing of the restrain was monitored by the nursing staff in the ward.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional occupational therapy
Description: They practised the same 10 tasks as in the SR-CIMT group described above. They received training for 2 weeks, 5 days a week (therapy days), the same as in the SR-CIMT and CIMT groups.
Study: NCT02770209

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: biomimetic cartilage matrix + autologous chondrocytes

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: arthroscopic debridement

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: microfracture surgery
Study: NCT03467009

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iPACT Intervention
Description: Brief in-person + tailored, daily 8-week text-message secondary prevention intervention.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control: Enhanced Usual Care (EUC)
Description: EUC group participants will receive standardized information on cyberbullying.
Study: NCT02593864

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Variable-Stiffness Shoe
Description: A load-modifying variable-stiffness shoe previously shown to reduce joint loading
Study: NCT02464111

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment 1: Control
Description: No supplement provided.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment 1: Control
Description: No supplement provided.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment 1: Control
Description: No supplement provided.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment 1: Control
Description: No supplement provided.
Study: NCT00262379

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: epoetin beta (NeoRecormon®)
Description: • Prescription of the epoetin beta : when blood concentration of hemoglobin is lower or equal to 12 g/dL in male or lower or equal to 11 g/dL in female
Study: NCT02001883

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Association low-dose statin and nutraceuticals

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Association low-dose statin and nutraceuticals
Study: NCT01218178

Intervention type: DRUG
Intervention: Sodium bicarbonate plus NAC
Description: 154 mEq/L sodium bicarbonate (infusion rate of 3 ml/Kg for 1 hour followed by 1 ml/Kg for 6 hours) plus NAC (1200 mg bid for 48 hours)

Intervention type: DRUG
Intervention: Saline hydration plus NAC
Description: 0.9% saline (1 ml/Kg for 12 hours) plus NAC (1200 mg bid for 48 hours)
Study: NCT02464111

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment 1: Control
Description: No supplement provided.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment 1: Control
Description: No supplement provided.
Study: NCT03467009

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iPACT Intervention- app
Description: Brief in-person + tailored, daily 8-week message secondary prevention intervention delivered via app.
Study: NCT03338959

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy
Study: NCT02899078

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study: NCT02555501

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PDT + Low level laser
Description: Two days before the laser treatment, the side of the oral cavity chosen for the experimental treatment was pigmented with aqueous solution of 0.005% methylene blue. A ball of sterile cotton was soaked in the dye solution and placed in the center of the lesion. Photosensitizer remained in the place for 5 minutes (pre-irradiation period). Then, to activate the dye, the lesion was irradiated with red light (InGaAlP / phosphide and Indium, Gallium and potassium).~From the 3rd to the 10th day was carried out only laser therapy. For laser therapy was first used infrared emitter laser unit with active medium AsGaAl (Gallium Arsenide and Aluminium). Then, we used the red emitter, whose active medium was the InGaAlP (phosphide and Indium, Gallium and Potassium).

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Low level laser
Description: Two days before the laser treatment, the lesion of the side of the oral cavity chosen for the control treatment was treated with ball of sterile cotton soaked in distilled water and the laser unit placed on the lesion without activation of the light. From the 3rd to the 10th day was carried out laser therapy. For laser therapy was first used infrared emitter laser unit with active medium AsGaAl (Gallium Arsenide and Aluminium). Then, we used the red emitter, whose active medium was the InGaAlP (phosphide and Indium, Gallium and Potassium).
Study: NCT04044144

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic Dietary Supplement
Description: Dietary supplement containing a combination of 8 probiotic strains
Study: NCT01546272

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Insorb resorbable staples
Description: Subcutanous suture using resorbable staples

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Monocryl resorbable wire
Description: Subcutanous suture using resorbable wire
Study: NCT01678976

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 2-093
Description: Tablets containing BIA 2-093 in doses of 300 and 600 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BIA 2-093
Description: Tablets containing BIA 2-093 in doses of 300 and 600 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxcarbazepine
Description: Tablets containing 300 mg and 600 mg of Trileptal®

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxcarbazepine
Description: Tablets containing 300 mg and 600 mg of Trileptal®
Study: NCT02850302

Intervention type: OTHER
Group type: OTHER
Intervention: PET with FDG
Description: A PET with FDG will be performed before the treatment is started and after 6 cycles of chemotherapy.

Intervention type: OTHER
Group type: OTHER
Intervention: Tumor exome analysis
Description: A biopsy of the tumor will be performed before the treatment is started and after 6 cycles of chemotherapy. Tumor exome analysis will be performed before treatment is started and after 6 cycles of chemotherapy.
Study: NCT02986178

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PVSRIPO
Description: A single dose of an oncolytic polio/rhinovirus recombinant (PVSRIPO)
Study: NCT04954482

Intervention type: OTHER
Intervention: No Intervention
Description: This is an observation study, with no intervention

Intervention type: OTHER
Intervention: No Intervention
Description: This is an observation study, with no intervention
Study: NCT00206726

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alemtuzumab plus Fludarabine
Description: Alemtuzumab (Campath) 30mg subcutaneous (SC) plus Fludarabine (Fludara) 25mg/m² intravenous (IV), Days 1-5 every 28 days
Study: NCT03989869

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Immediate treatment
Description: Early Medical Abortion treatment, when ultrasound does not yet have conclusive signs of intrauterine pregnancy
Study: NCT02185521

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: patient assessment
Description: Patient clinician status assessment based on Hemodynamic Instability Indicator (HII) trend. The HII indicator combines existing data such as physiologic parameters (Heart Rate, HR; Blood Pressure, BP), laboratory measurements (Albumin; Hematocrit, HCT; Bicarbonate; White Blood Cell, WBC; Blood Urea Nitrogen, BUN), and ADT information (age). HII will be displayed on charting workstation (Workstation on Wheels, WOW). Nurse's role will be to observe the value of HII while accessing WOW desktop (during regular charting), interpret HII value, and share this information to the physician when indicative of potential patient hemodynamic instability to trigger patient clinical status assessment. This intervention is associated with Experimental Study Arm: visible HII.
Study: NCT03751267

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tuina (massage)
Description: Tuina is massage based on Traditional Chinese Medicine (TCM) principles.
Study: NCT00875758

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Removal of CSF through ventricular access device
Description: Ventricular access devices (VADs) are surgically implanted when cranial ultrasound measures reach treatment group-specific criteria. For the standard-threshold arm, VADs will be implanted when the age-adjusted ventricular index shows the ventricles to be at the 97th percentile + 2 standard deviations. Cerebrospinal fluid is then removed from the VADs 1-3 times daily as required to maintain ventricles within these parameters.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Removal of CSF through a ventricular access device
Description: Ventricular access devices (VADs) are surgically implanted when cranial ultrasound measures reach treatment group-specific criteria. For the standard-threshold arm, VADs will be implanted when the age-adjusted ventricular index shows the ventricles to be at the 97th percentile. Cerebrospinal fluid is then removed from the VADs 1-3 times daily as required to maintain ventricles within these parameters.